KMT2AR
Clinical trials for KMT2AR explained in plain language.
Never miss a new study
Get alerted when new KMT2AR trials appear
Sign up with your email to follow new studies for KMT2AR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat leukemia: experimental drug enters human trials
Disease control Recruiting nowThis study is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and effective. It will involve 420 adults with acute myeloid leukemia (AML) who have specific genetic changes in their cancer cells. The main goals are to find the …
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug cocktail tested for aggressive leukemia that has returned
Disease control Recruiting nowThis early-stage trial is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy and has specific …
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC